# US 2025/0144192 A1 · Novel peptides and combination of peptides for use in immunotherapy against breast cancer and other cancers

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0144192 A1
- Document ID: US20250144192A1
- Status: Published application
- Kind: A1
- Application number: 19/016,817
- Filed: 2025-01-10
- Published: 2025-05-08
- Earliest claimed: 2015-12-22
- Assignees: Immatics Biotechnologies GmbH
- Applicants: Immatics Biotechnologies GmbH
- Inventors: Andrea MAHR; Toni WEINSCHENK; Helen HOERZER; Oliver SCHOOR; Jens FRITSCHE; Harpreet SINGH
- Web page: https://patentgrep.com/patent/US20250144192A1

## CPC

- A61K 39/0011: {Cancer antigens}
- A61K 35/17: Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes (when activated by a specific antigen A61K39/00)
- A61K 38/08: Peptides having 5 to 11 amino acids {(A61K38/043 - A61K38/046 take precedence)}
- A61K 38/1709: {from mammals}
- A61K 40/11: T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
- A61K 40/42: Cancer antigens
- A61P 35/00: Antineoplastic agents
- A61P 35/02: specific for leukemia
- C07K 7/06: having 5 to 11 amino acids
- C07K 14/4748: {Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE}
- C07K 14/7051: {T-cell receptor (TcR)-CD3 complex}
- C07K 14/721: {Steroid/thyroid hormone superfamily, e.g. GR, EcR, androgen receptor, oestrogen receptor}
- C07K 16/00: Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K 16/2833: {against MHC-molecules, e.g. HLA-molecules}
- C12N 15/115: Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith {; Nucleic acids binding to non-nucleic acids, e.g. aptamers}
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- A61K 39/39: characterised by the immunostimulating additives, e.g. chemical adjuvants
- A61K 2039/812: {Breast}
- C07K 7/00: Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K 2317/41: Glycosylation, sialylation, or fucosylation
- C12N 2310/16: Aptamers
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

## Claims

### Claim 1

A method of treating a patient who has cancer, comprising administering to said patient a population of activated T cells that kill cancer cells that present on the cell surface a peptide consisting of the amino acid sequence of FSFPVSVGV (SEQ ID NO: 20),
wherein the cancer is selected from breast cancer, bile duct cancer, esophageal cancer, gallbladder cancer, gastric cancer, melanoma, non-Hodgkin lymphoma, non-small cell lung cancer, ovarian cancer, small cell lung cancer, urinary bladder cancer, uterine cancer, pancreatic cancer, and renal cancer.

### Claim 2 (depends on 1)

The method of claim 1, wherein the activated T cells are cytotoxic T cells produced by introducing into T cells a nucleic acid encoding a T cell receptor (TCR) that binds a peptide consisting of the amino acid sequence of FSFPVSVGV (SEQ ID NO: 20) in a complex with an MHC class I molecule.

### Claim 3 (depends on 1)

The method of claim 1, wherein the cancer is breast cancer.

### Claim 4 (depends on 1)

The method of claim 1, wherein the cancer is bile duct cancer.

### Claim 5 (depends on 1)

The method of claim 1, wherein the cancer is esophageal cancer.

### Claim 6 (depends on 1)

The method of claim 1, wherein the cancer is gallbladder cancer.

### Claim 7 (depends on 1)

The method of claim 1, wherein the cancer is gastric cancer.

### Claim 8 (depends on 1)

The method of claim 1, wherein the cancer is melanoma.

### Claim 9 (depends on 1)

The method of claim 1, wherein the cancer is non-Hodgkin lymphoma.

### Claim 10 (depends on 1)

The method of claim 1, wherein the cancer is non-small cell lung cancer.

### Claim 11 (depends on 1)

The method of claim 1, wherein the cancer is ovarian cancer.

### Claim 12 (depends on 1)

The method of claim 1, wherein the cancer is small cell lung cancer.

### Claim 13 (depends on 1)

The method of claim 1, wherein the cancer is urinary bladder cancer.

### Claim 14 (depends on 1)

The method of claim 1, wherein the cancer is uterine cancer.

### Claim 15 (depends on 1)

The method of claim 1, wherein the cancer is pancreatic cancer.

### Claim 16 (depends on 1)

The method of claim 1, wherein the cancer is renal cancer.

### Claim 17 (depends on 1)

The method of claim 1, further comprising administering to said patient at least one adjuvant selected from the group consisting of anti-CD40 antibody, imiquimod, resiquimod, GM-CSF, cyclophosphamide, sunitinib, bevacizumab, interferon-alpha, interferon-beta, CpG oligonucleotides, poly-(I:C), RNA, sildenafil, particulate formulations with poly(lactide co-glycolide) (PLG), virosomes, interleukin (IL)-1, IL-2, IL-4, IL-7, IL-12, IL-13, IL-15, IL-21, and IL-23.

### Claim 18

A method of eliciting an immune response in a patient who has cancer, comprising administering to said patient a population of activated T cells that kill cancer cells that present on the cell surface a peptide consisting of the amino acid sequence of FSFPVSVGV (SEQ ID NO: 20),
wherein the cancer is selected from breast cancer, bile duct cancer, esophageal cancer, gallbladder cancer, gastric cancer, melanoma, non-Hodgkin lymphoma, non-small cell lung cancer, ovarian cancer, small cell lung cancer, urinary bladder cancer, uterine cancer, pancreatic cancer, and renal cancer.

### Claim 19 (depends on 18)

The method of claim 18, wherein the activated T cells are cytotoxic T cells produced by introducing into T cells a nucleic acid encoding a T cell receptor (TCR) that binds a peptide consisting of the amino acid sequence of FSFPVSVGV (SEQ ID NO: 20) in a complex with an MHC class I molecule.

### Claim 20 (depends on 18)

The method of claim 18, further comprising administering to said patient at least one adjuvant selected from the group consisting of anti-CD40 antibody, imiquimod, resiquimod, GM-CSF, cyclophosphamide, sunitinib, bevacizumab, interferon-alpha, interferon-beta, CpG oligonucleotides, poly-(I:C), RNA, sildenafil, particulate formulations with poly(lactide co-glycolide) (PLG), virosomes, interleukin (IL)-1, IL-2, IL-4, IL-7, IL-12, IL-13, IL-15, IL-21, and IL-23.
